| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.03 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.04 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.094 | 0.04 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.065 | 0.04 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.065 | 0.04 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.067 | 0.04 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |